{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T01:36:32Z","timestamp":1747186592115,"version":"3.40.5"},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022960","name":"Australasian Pharmaceutical Science Association","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100022960","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Obstet and Gynaecol"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>This pilot study aimed to assess the utility of an oral progesterone treatment protocol for women who commenced medical abortion and then changed their mind and wished instead to maintain their pregnancy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The <jats:bold>P<\/jats:bold>rogesterone\u2010<jats:bold>A<\/jats:bold>fter\u2010<jats:bold>M<\/jats:bold>ifepristone\u2014<jats:bold>p<\/jats:bold>ilot for <jats:bold>e<\/jats:bold>fficacy and <jats:bold>r<\/jats:bold>eproducibility (PAMper) trial was designed as a prospective single\u2010arm pilot clinical trial, conducted via telehealth. Women aged 18 to 45\u2009years in Australia who reported ingesting mifepristone within the last 72\u2009h to initiate medical abortion and had not taken misoprostol were included. Initial contact was by a web\u2010based form. Following informed consent, participants were prescribed oral progesterone to be taken 400\u2009mg twice per day for 3\u2009days then 400\u2009mg at night until completion of a 19\u2009day course. Pregnancy viability was assessed by ultrasound scan after 14\u2009days of progesterone treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between October 2020 and June 2021, nine women contacted the PAMper trial, of whom six enrolled and commenced progesterone treatment. These women reported ingesting mifepristone at 40\u201370\u2009days of gestation, with progesterone being commenced within 5.7\u201372\u2009h of mifepristone ingestion. Five participants had ongoing, live pregnancies at the primary endpoint (ultrasound at &gt;2\u2009weeks). One participant had a miscarriage after 9\u2009days of progesterone treatment. There were no clinically significant adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This small study demonstrated a clinically sound protocol for researching the use of progesterone\u2010after\u2010mifepristone for women in this circumstance. Results of this pilot study support the need for further larger scale trials in this field.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jog.15826","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:58:41Z","timestamp":1699577921000},"page":"182-189","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Progesterone after mifepristone: A pilot prospective single arm clinical trial for women who have changed their mind after commencing medical abortion"],"prefix":"10.1111","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0023-4275","authenticated-orcid":false,"given":"Joseph V.","family":"Turner","sequence":"first","affiliation":[{"name":"University of New England Faculty of Medicine and Health  Armidale New South Wales Australia"},{"name":"University of Queensland Faculty of Medicine  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Garratt","sequence":"additional","affiliation":[{"name":"University of New England Faculty of Medicine and Health  Armidale New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas A.","family":"McLindon","sequence":"additional","affiliation":[{"name":"University of Queensland Faculty of Medicine  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Barwick","sequence":"additional","affiliation":[{"name":"University of New England Faculty of Medicine and Health  Armidale New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Joy","family":"Spark","sequence":"additional","affiliation":[{"name":"University of New England Faculty of Medicine and Health  Armidale New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rhm.2015.10.002"},{"volume-title":"Pharmaceutical benefits scheme and repatriation pharmaceutical benefits scheme section 85 supply data","year":"2022","author":"Australian Government Department of Health","key":"e_1_2_8_3_1"},{"volume-title":"Product information\u2014MS\u20102","year":"2017","author":"Australian Register of Therapeutic Goods (ARTG)","key":"e_1_2_8_4_1"},{"issue":"1","key":"e_1_2_8_5_1","first-page":"3","article-title":"A case series detailing the successful reversal of the effects of mifepristone using progesterone","volume":"33","author":"Delgado G","year":"2018","journal-title":"Issues Law Med"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/13625187.2017.1412424"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000003620"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2015.06.001"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R252"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/13625187.2018.1459545"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.721"},{"issue":"1","key":"e_1_2_8_12_1","first-page":"3","article-title":"Embryo survival after mifepristone: a systematic review of the literature","volume":"32","author":"Davenport ML","year":"2017","journal-title":"Issues Law Med"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0517-5"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0560-z"},{"volume-title":"Ectopic pregnancy and miscarriage: diagnosis and initial management (NG126 update). [C] Progestogens for preventing miscarriage","year":"2021","author":"National Institute for Health and Care Excellence","key":"e_1_2_8_15_1"},{"volume-title":"Ectopic pregnancy and miscarriage: diagnosis and initial management (NG126)","year":"2019","author":"National Institute for Health and Care Excellence","key":"e_1_2_8_16_1"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deab285"},{"volume-title":"Prometrium 100 and 200\u2009mg, soft capsule","year":"2016","author":"Australian Register of Therapeutic Goods (ARTG)","key":"e_1_2_8_18_1"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.12147"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(84)90014-3"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-2115(01)00522-X"},{"volume-title":"Product information\u2014mifepristone Linepharma 200\u2009mg tablet","year":"2017","author":"Australian Register of Therapeutic Goods (ARTG)","key":"e_1_2_8_22_1"},{"volume-title":"Abortion Care Guideline","year":"2022","author":"Sexual and Reproductive Health and Research","key":"e_1_2_8_23_1"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fgwh.2021.705611"},{"key":"e_1_2_8_25_1","unstructured":"Women's Health Committee.The use of mifepristone for medical termination of pregnancy (C\u2010Gyn 21). The Royal Australian and New Zealand College of Obstetricians and Gynaecologists.2007rev 2019."},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2022.06.010"}],"container-title":["Journal of Obstetrics and Gynaecology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jog.15826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:29:51Z","timestamp":1706833791000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/jog.15826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1111\/jog.15826"],"URL":"https:\/\/doi.org\/10.1111\/jog.15826","archive":["Portico"],"relation":{},"ISSN":["1341-8076","1447-0756"],"issn-type":[{"type":"print","value":"1341-8076"},{"type":"electronic","value":"1447-0756"}],"subject":[],"published":{"date-parts":[[2023,11,9]]},"assertion":[{"value":"2023-08-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}